PharmaTimes - September 2018

Though we mainly keep our eye on UK pharma at PharmaTimes, there’s no doubt that the industry here will have to become increasingly interconnected with other countries to face challenges ahead – and especially so in the ever-complicated world of clinical trials.

Of course, in the modern world that’s easier said than done – so we’ve asked four clinical research experts to give their views on what the biggest challenges will be for global clinical trials in the near future and how pharma can overcome them (p30).

Sticking with the global theme, we look at the potential changes to drug pricing in the US on p22 – while on p38 former ABPI president Lisa Anson shares her opinions on what the UK industry can learn from the US and why she’s given up big pharma to head a biotech.

Elsewhere we have articles on recent competition law cases (p24), new approaches to T-cell therapy (p26) and challenges in regenerative medicine (p36).

September 2018 - magazine highlights

SmartPeople: Lisa Anson

The former president of AstraZeneca UK and the ABPI has gi...

Go global

For successful clinical trials today, it’s necessary to go...

Late to regenerate

Are current regulatory frameworks hindering  development o...

The best pharma tweeters 
in the UK

A new report looks at the effectiveness of dedicated UK tw...

Company focus: Adaptimmune

Despite the excitement surrounding T-cell therapy, CAR-T c...

Patient Files: Immune thrombocytopenic purpura

Derek Elston, trustee of the ITP Support Association, tell...

How the 10-year plan could influence spending

Longer-term budgeting and integrated care systems could tr...

Trump takes 
on big pharma

The president's FDA commissioner could become a “Scrooge”...

Competition law and pharma: a picture in flux

The CMA has tackled some major pharma cases since its ince...

SmartPeople: Kris Sterkens

The industry vet and current company group chairman of Jan...